Business
Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have
About this update from Celldex Therapeutics, Inc.
[{"type":"text","content":"HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020, which this year will be held digitally June 6-8, 2020. The study will be presented by Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy at the Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin. Dr. Maurer is also head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus and Angioedema and the Dermatological Allergology Lab. Dr. Maurer is a leading medical expert in urticaria and his research focuses on the physiological and pathological functions of mast cells.\n Presentation details: Presentation #1829: CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in serum tryptase and a favorable safety profile in a phase 1a healthy volunteer study Date: Pre-recorded digital content will be available beginning June 6, 2020 at 9:00 am CEST (3:00 am EDT) through June 8, 2020 at 7:15 pm CEST (1:15 pm EDT) on the EAACI websiteSession type: Late Breaking Poster Presentation (LB PDS)Session number: LB PDS 02Session category: Allergy and clinical immunology Information included in the abstract was current as of the time of submission in March. The poster presentation will include complete results from the study. CDX-0159 is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells. In certain inflammatory diseases, such as chronic urticarias, mast cell degranulation plays a central role in the onset and progression of the disease. Enrollment and treatment of healthy subjects was recently completed in the ongoing Phase 1 single ascending dose escalation study of CDX-0159 in healthy subjects. This study is designed to evaluate the safety profile, pharmacokinetics and pharmacodynamics of CDX-0159 and to select a dose for further study in mast cell driven diseases. The Phase 1 study also evaluates plasma tryptase levels in healthy subjects. Tryptase is an enzyme synthesized...